By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.
The Voice of People With Breast Cancer
Education
Publications
& Resources
Clinical Trials Connected
Research is critical in helping us better understand breast cancer, and equally important is your awareness of these advancements and opportunities to participate. Our e-newsletter, Clinical Trials Connected, aims to connect you with crucial research updates and clinical trials to help you stay informed about the latest advancements in breast cancer care.
On this page you can find the information from past issues. If you would like to receive CTC directly to your inbox, or any of our other newsletters, you can subscribe here.
»
November 2024: Highlights from the 2024 Canadian Association of Nurses in Oncology Conference. Topics include:
- Impact of Breast Cancer on Women’s Distress and Quality of Life
- YACC Recover Study – Quality of Life in Young Adults with Cancer
- Insights into the Cancer Patient Journey – South Asian Patients
- Body Image and Breast Cancer – A Photovoice Exploration
- Male Breast Cancer
- Innovative Approach to Providing Community Cancer Support Programs
»
October 2024: Highlights from the ESMO Congress. Topics include:
- Breastfeeding is possible for young patients with HR+ breast cancer
- Adding ovarian function suppression to endocrine therapy improves survival in high-risk premenopausal breast cancer patients
- Final results for KEYNOTE 522 exploring pembrolizumab plus chemotherapy for early-stage triple negative breast cancer
- Combining ribociclib with an aromatase inhibitor improves survival rates in patients with early HR+, HER2- breast cancer
- Promising results from ELECTRA trial show clinical benefit in metastatic breast cancer with elacestrant and abemaciclib combo
- T-DXd continues to show promise for HER2+ mBC with brain metastases
- Abemaciclib could be a more effective first-line therapy for some HR+, HER2- mBC patients with aggressive disease
- and more
»
»
August 2024: Highlights from ASCO. Topics include:
- Biomarkers predicting response to immunotherapy more common in Black women
- NATALEE Trial shows ribociclib significantly reduces risk of recurrence in high-risk, node-negative early breast cancer
- Adjuvant avelumab extends survival in high-risk TNBC
- Tailored chemotherapy can reduce toxicity and side effects for Black patients
- Abemaciclib improves outcomes in HR+, HER2- metastatic breast cancer after initial treatment
- Inavolisib extends treatment time and delays progression in metastatic patients with PIK3CA mutation
- Racial disparities in targeted therapy for PIK3CA mutated ER+, HER2- metastatic breast cancer
»
August 2024: Highlights from ARCC and ESMO. Topics include:
- The cost of breast cancer
- Screening variations by provinces
- Availability and quality of educational breast cancer resources
- Study results for pertuzumab in HER2-positive metastatic breast cancer patients
- The MORPHEUS-panBC trial in combination therapy for atezolizumab and sacituzumab
- Results from the SOFT and TEXT trials on exemestane plus ovarian suppression
-
Results from a global assisted reproductive techniques study for BRCA carriers
-
Pooled data study results for a genomic test for HER2+ early-stage breast cancers
SHARE
Our Stories
Events
Receive updates by email Subscribe Now
About CBCN
CBCN strives to voice the views and concerns of breast cancer patients through education, advocacy activities, and the promotion of information sharing.
Canadian Breast Cancer Network
185 Somerset St. West Suite 318, Ottawa, ON Canada K2P 0J2
Tel: 613-230-3044
Toll-free: 1-800-685-8820
Email Us
